Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors

A compound of Formula 1:

• or a pharmaceutically acceptable salt thereof, wherein in Formula 1,
• L1 is —CH2—;
• L2 is —NH—SO2—;
• each of R3, R4, R5, and R6 is hydrogen;
• Ar1 is
• wherein each of R1a and R2a is independently selected from hydrogen, C1-10 alkyl, and C1-10 alkyl substituted by one or more of substituents which are independently hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —ORa, —S(O)tRa— (wherein t is 1 or 2), —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tRa (wherein t is 1 or 2), —S(O)tRa (wherein t is 1 or 2), —S(O)tORa (wherein t is 1 or 2), —S(O)tN(Ra)2 (where t is 1 or 2), or PO(ORa)2 wherein each Ra is independently hydrogen or C1-3 alkyl;
• and wherein —NR1R2 is selected from:
• wherein,
• R7 is selected from hydrogen, OH, C1-10 alkyl, and substituted C1-10 alkyl;
• and
• Ar2 is a 5- to 18-membered heteroaryl.